TempraMed

Company Overview

Snapshot

Founded in October 2014 by Ron Nagar and Elina Nagar, TempraMed operates with 11–50 employees. The company has raised a total of $10.18M across 6 funding rounds. In October 2025, TempraMed became publicly listed on the CSE.

Business overview

TempraMed is a Health Tech & Life Sciences company specializing in medical devices for temperature-sensitive injectable medications. The company develops patent-protected technology that provides temperature control without external power sources and tracks medication usage. Its core products, such as the VIVI Cap and VIVI Epi, utilize smart thermal shields combining ultrahigh vacuum thermal insulation and phase-change materials to maintain medication potency. TempraMed serves patients, healthcare providers, and payors in the chronic disease and diabetes markets globally, with a focus on medical products and monitoring solutions.

Strategic signal

TempraMed is rapidly expanding its global footprint and strategic partnerships, highlighted by its recent agreement in June 2026 with McKesson Medical-Surgical to accelerate North American growth and launch its full portfolio across B2B channels. This expansion with a major distributor like McKesson signals strong market validation and a significant push towards broader commercialization, indicating a positive trajectory for investor confidence and market penetration in key healthcare sectors.

Company Intelligence Q&A

When did TempraMed become a public company?

TempraMed became publicly listed on the CSE in October 2025.

What was a significant product launch for TempraMed in early 2026?

In January 2026, TempraMed launched its new product, VIVI Med, designed to unlock growth opportunities in high-value biologics and injectable medications.

Which major partnership did TempraMed announce in June 2026?

In June 2026, TempraMed expanded its strategic partnership with McKesson Medical-Surgical to accelerate North American growth and launch its full portfolio across B2B channels.

What intellectual property milestone did TempraMed achieve in March 2026?

In March 2026, TempraMed strengthened its global intellectual property position with a granted Chinese patent for its newest product, VIVI Box.

What was TempraMed's activity in the Israeli market in early 2026?

In February 2026, TempraMed launched a national brick-and-mortar pharmacy rollout, shipping products to Maccabi Pharmacies across Israel, following a strategic agreement with Maccabi Healthcare Services in December 2025.